Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Savara Inc | 2,368,194 | reported | 20 Jan 2017 | tx 22+15,139,744−1,205,000 |
| Lineage Cell Therapeutics, Inc. | 255,516 | reported | 12 Mar 2026 | tx 77+16,091,169−1,399,864 |
| INKSURE TECHNOLOGIES INC. | 48,528 | reported | 15 Mar 2018 | tx 4+328,668 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 12 Mar 2026 | PURCHASE | Lineage Cell Therapeutics, Inc. | 15,000 | 1.63 USD | first after silence |
| 05 Mar 2026 | GRANT_AWARD | Lineage Cell Therapeutics, Inc. | 3,250,000 | 0.00 USD | deriv |
| 11 Feb 2026 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,250 | — | |
| 11 Feb 2026 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 12,869 | 1.80 USD | |
| 11 Feb 2026 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,250 | 0.00 USD | deriv |
| 19 Dec 2025 | GRANT_AWARD | Lineage Cell Therapeutics, Inc. | 8,925 | — | |
| 19 Dec 2025 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 334 | 1.68 USD | |
| 10 Mar 2025 | GRANT_AWARD | Lineage Cell Therapeutics, Inc. | 2,300,000 | 0.00 USD | deriv |
| 11 Feb 2025 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | — | |
| 11 Feb 2025 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 12,547 | 0.65 USD | |
| 11 Feb 2025 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | 0.00 USD | deriv |
| 21 Nov 2024 | PURCHASE | Lineage Cell Therapeutics, Inc. | 40,000 | 0.60 USD | |
| 24 May 2024 | PURCHASE | Lineage Cell Therapeutics, Inc. | 10,000 | 1.05 USD | first after silence |
| 07 Mar 2024 | GRANT_AWARD | Lineage Cell Therapeutics, Inc. | 1,900,000 | 0.00 USD | deriv |
| 11 Feb 2024 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | — | |
| 11 Feb 2024 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 12,806 | 1.08 USD | |
| 11 Feb 2024 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | 0.00 USD | deriv |
| 09 Mar 2023 | GRANT_AWARD | Lineage Cell Therapeutics, Inc. | 1,900,000 | 0.00 USD | deriv |
| 11 Feb 2023 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | — | |
| 11 Feb 2023 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 12,744 | 1.35 USD | |
| 11 Feb 2023 | EXERCISE | Lineage Cell Therapeutics, Inc. | 31,249 | 0.00 USD | deriv |
| 30 Jun 2022 | EXERCISE | Lineage Cell Therapeutics, Inc. | 15,450 | — | |
| 30 Jun 2022 | TAX_WITHHOLDING | Lineage Cell Therapeutics, Inc. | 5,343 | 1.58 USD | |
| 30 Jun 2022 | EXERCISE | Lineage Cell Therapeutics, Inc. | 15,450 | 0.00 USD | deriv |
| 31 Mar 2022 | PURCHASE | Lineage Cell Therapeutics, Inc. | 6,400 | 1.53 USD |
6 purchases reported after at least 12 months of silence — most recent on 12 Mar 2026.